Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 165

Sort by

Sort Order Select

Journal Articles

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma

Xiaosheng Wu, Mary Stenson, Jithma Abeykoon, Kevin Nowakowski, Lianwen Zhang, Joshua Lawson, Linda Wellik, Ying Li, Jordan Krull, Kerstin Wenzl, Anne J. Novak, Stephen M. Ansell, Gail A. Bishop, Daniel D. Billadeau, Kah Whye Peng, Francis Giles, Daniel M. Schmitt, Thomas E. Witzig

Blood (2019) 134 (4): 363–373.

https://doi.org/10.1182/blood.2018874560

Published: 2019

Includes: Supplemental data

Journal Articles

Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),

Michael E O'Dwyer, MD, FRCPI, FRCPath, Ronan Swords, MD, MRCPI, FRCPath, Francis Giles, MD FRCPI FRCPath, Mary Frances McMullin, MD, Philipp D. le Coutre, MD, Arnon Nagler, Stephen Langabeer, Marzena Wieczorkowska, Cliona McDowell, Karine Egan, Brian Moulton, Eibhlin Conneally, MB, MRCPI, FRCPath, PhD

Blood (2011) 118 (21): 3774.

https://doi.org/10.1182/blood.V118.21.3774.3774

Published: 2011

Journal Articles

Epidemiologic study on survival of chronic myeloid leukemia and Ph + acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

Franck E. Nicolini, Michael J. Mauro, Giovanni Martinelli, Dong-Wook Kim, Simona Soverini, Martin C. Müller, Andreas Hochhaus, Jorge Cortes, Charles Chuah, Inge H. Dufva, Jane F. Apperley, Fumiharu Yagasaki, Jay D. Pearson, Senaka Peter, Cesar Sanz Rodriguez, Claude Preudhomme, Francis Giles, John M. Goldman, Wei Zhou

Blood (2009) 114 (26): 5271–5278.

https://doi.org/10.1182/blood-2009-04-219410

Published: 2009

Journal Articles

A Common but Overlooked Mechanism of BCR-ABL1 Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.

Jean-Marie Bruey, Hagop M. Kantarjian, MD, Wanlong Ma, Chen-Hsiung Yeh, Tai-Sung Lee, Susan O'Brien, Francis Giles, MD, Zeev Estrov, MD, Jorge Cortes-Franco, MD, Maher Albitar, MD

Blood (2009) 114 (22): 2179.

https://doi.org/10.1182/blood.V114.22.2179.2179

Published: 2009

Journal Articles

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse

Francis Giles, Norbert Vey, Daniel DeAngelo, Karen Seiter, Wendy Stock, Robert Stuart, Darinka Boskovic, Arnaud Pigneux, Martin Tallman, Joseph Brandwein, Jonathan Kell, Tadeusz Robak, Peter Staib, Xavier Thomas, Ann Cahill, Maher Albitar, Susan O'Brien

Blood (2009) 114 (19): 4027–4033.

https://doi.org/10.1182/blood-2009-06-229351

Published: 2009

Journal Articles

Response:Plasma and JAK2 mutation

Maher Albitar, Wanlong Ma, Hagop Kantarjian, Francis Giles

Blood (2009) 114 (1): 224.

https://doi.org/10.1182/blood-2009-04-215442

Published: 2009

Journal Articles

Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)

Elias Jabbour, MD, Hagop M Kantarjian, Michele Baccarani, MD, Philipp D. le Coutre, MD, Ariful Haque, Neil J. Gallagher, MD, PhD, Jorge Cortes, MD, Francis Giles, MD

Blood (2008) 112 (11): 3215.

https://doi.org/10.1182/blood.V112.11.3215.3215

Published: 2008

Journal Articles

Hypermethylation of O 6 -Methylguanine-DNA Methyltransferase (MGMT) Predicts Response to Laromustine (Cloretazine®) in Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Ilan Bernstein, MD, Francis Giles, MD, Susan O’Brien, MD, Elizabeth Sullivan, MS, Norbert Vey, MD, Allen S. Yang, MD, PhD

Blood (2008) 112 (11): 4463.

https://doi.org/10.1182/blood.V112.11.4463.4463

Published: 2008

Journal Articles

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

Robert Hills, MA, MSc, DPhil, Susan O’Brien, M.D., Verena Karsten, PhD, Alan K. Burnett, MD, FRCP, Francis Giles, MD

Blood (2008) 112 (11): 2960.

https://doi.org/10.1182/blood.V112.11.2960.2960

Published: 2008

Journal Articles

Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

Philipp D. le Coutre, MD, Francis Giles, MD, Andreas Hochhaus, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, Gert Ossenkoppele, MD, PhD, Ariful Haque, Neil J. Gallagher, MD, PhD, Michele Baccarani, MD, Jorge Cortes, MD, Hagop M Kantarjian

Blood (2008) 112 (11): 3229.

https://doi.org/10.1182/blood.V112.11.3229.3229

Published: 2008

Journal Articles

Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis

Jeffrey H. Lipton, MD, PhD, Philipp D. le Coutre, MD, Jim Wang, PhD, Mindy Yang, PharmD, Tomasz Szczudlo, MD, Francis Giles, MD

Blood (2008) 112 (11): 3233.

https://doi.org/10.1182/blood.V112.11.3233.3233

Published: 2008

Journal Articles

Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study

Francis Giles, MD, Philipp D. le Coutre, MD, Kapil N. Bhalla, MD, Gert J Ossenkoppele, MD, PhD, Giuliana Alimena, MD, Ariful Haque, M.S., Neil J. Gallagher, MD, PhD, Hagop M Kantarjian

Blood (2008) 112 (11): 3234.

https://doi.org/10.1182/blood.V112.11.3234.3234

Published: 2008

Journal Articles

Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.

Hagop M Kantarjian, Francis Giles, MD, Kapil N. Bhalla, MD, Richard A. Larson, MD, Norbert Gattermann, MD, Oliver G. Ottmann, MD, Ariful Haque, M.S., Neil J. Gallagher, MD, PhD, Michele Baccarani, MD, Philipp D. le Coutre, MD

Blood (2008) 112 (11): 3238.

https://doi.org/10.1182/blood.V112.11.3238.3238

Published: 2008

Journal Articles

Survival after Complete Response to Treatment with Laromustine (CLORETAZINE ® ) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML).

Susan O’Brien, M.D., Gary Schiller, Robert Kenneth Stuart, MD, Diana Hudak, Francis Giles, MD

Blood (2008) 112 (11): 940.

https://doi.org/10.1182/blood.V112.11.940.940

Published: 2008

Journal Articles

A Phase I/II Study with CP-4055 in Patients with Haematologic Malignancies.

Susan O’Brien, M.D., David A. Rizzieri, MD, Norbert Vey, MD, Hagop M Kantarjian, Tove Flem Jacobsen, Bo I Nilsson, MD, PhD, Karin Staudacher, Francis Giles, MD

Blood (2008) 112 (11): 949.

https://doi.org/10.1182/blood.V112.11.949.949

Published: 2008

Journal Articles

Higher detection rate of JAK2 mutation using plasma

Wanlong Ma, Hagop Kantarjian, Xi Zhang, Weimin Sun, Arlene M. Buller, Iman Jilani, Joyce G. Schwartz, Francis Giles, Maher Albitar

Blood (2008) 111 (7): 3906–3907.

https://doi.org/10.1182/blood-2008-02-139188

Published: 2008

Journal Articles

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Blood (2008) 111 (4): 1834–1839.

https://doi.org/10.1182/blood-2007-04-083196

Published: 2008

Journal Articles

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

Jorge Cortes, Elias Jabbour, Hagop Kantarjian, C. Cameron Yin, Jianqin Shan, Susan O'Brien, Guillermo Garcia-Manero, Francis Giles, Megan Breeden, Nubia Reeves, William G. Wierda, Dan Jones

Blood (2007) 110 (12): 4005–4011.

https://doi.org/10.1182/blood-2007-03-080838

Published: 2007

Journal Articles

Overexpression of JAK2 mRNA in Chronic Myeloproliferative Disease and Its Implication on Mutation Testing and Biology of Disease.

Wanlong Ma, Xi Zhang, Iman Jilani, Ph.D., Zhong Zhang, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Francis Giles, M.D., Susan O’Brien, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2554.

https://doi.org/10.1182/blood.V110.11.2554.2554

Published: 2007

Journal Articles

Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (FTS), a Novel Oral Ras Inhibitor, in Patients with Refractory Hematologic Malignancies.

Gautam Borthakur, MD, Farhad Ravandi, MD, Susan O’Brien, MD, Miloslav Beran, MD, Betsy Williams, RN, Howard Goldsweig, MD, Francis Giles, MD

Blood (2007) 110 (11): 1600.

https://doi.org/10.1182/blood.V110.11.1600.1600

Published: 2007

NARROW

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma

Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),

Epidemiologic study on survival of chronic myeloid leukemia and Ph + acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

A Common but Overlooked Mechanism of BCR-ABL1 Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse

Response:Plasma and JAK2 mutation

Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)

Hypermethylation of O 6 -Methylguanine-DNA Methyltransferase (MGMT) Predicts Response to Laromustine (Cloretazine®) in Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis

Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study

Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.

Survival after Complete Response to Treatment with Laromustine (CLORETAZINE ® ) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML).

A Phase I/II Study with CP-4055 in Patients with Haematologic Malignancies.

Higher detection rate of JAK2 mutation using plasma

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

Overexpression of JAK2 mRNA in Chronic Myeloproliferative Disease and Its Implication on Mutation Testing and Biology of Disease.

Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (FTS), a Novel Oral Ras Inhibitor, in Patients with Refractory Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only